Cartesian Therapeutics Q1 EPS $(0.68) Beats $(0.71) Estimate, Sales $1.10M Beat $785.71K Estimate

Cartesian Therapeutics (NASDAQ: RNAC) reported quarterly losses of $(0.68) per share which beat the analyst consensus estimate of $(0.71) by 4.23 percent. This is a 93.52 percent increase over losses of $(10.50) per share from the same period last year. The company reported quarterly sales of $1.10 million which beat the analyst consensus estimate of $785.71 thousand by 40.00 percent. This is a 81.16 percent decrease over sales of $5.84 million the same period last year.